- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00226005
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy.
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.
Panoramica dello studio
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259
- Scottsdale Healthcare
-
Tucson, Arizona, Stati Uniti, 85724
- University of Arizona/Arizona Cancer Center
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211-18500
- Tower Hematology Oncology Medical Group
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21231
- Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Virginia Piper Cancer Institute/Abbott Northwestern Hospital
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78229
- South Texas Oncology and Hematology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age > 18
- Zubrod performance status of 0 - 2
- Histological or cytological diagnosis of pancreatic adenocarcinoma
- Measurable or evaluable disease determined as per RECIST criteria
- Life expectancy > 12 weeks
- Written informed consent
- Patients must have failed or progressed on prior gemcitabine-based therapy for advanced or metastatic disease.
Exclusion Criteria:
- Islet cell or neuroendocrine carcinomas of the pancreas.
- History or presence of central nervous system disease.
- Patients with a history of another primary malignancy < 5 years
- Prior chemo therapy < 21 days prior to registration.
- Prior biologic or immunotherapy < 14 days prior to registration
- Prior full field radiotherapy < 28 days or limited field radiotherapy < 14 days prior to registration.
- Major surgery < 28 days prior to registration.
- Patients who have received investigational drugs < 28 days prior to registration.
- Prior therapy with anti-VEGF agents.
- Pleural effusion or ascites that causes respiratory compromise.
- Female patients who are pregnant or breast feeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Vatalanib
Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
|
One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
To evaluate the 6-month survival rate and time to progression in pancreatic cancer patients treated with PTK787/ZK222584.
Lasso di tempo: DSMC Schedule
|
The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives. Safety Issue: the only endpoint/outcome measure that was a safety issue was the second one (safety and tolerability of PTK) |
DSMC Schedule
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
To assess the response rates of patients treated with PTK787/ZK222584.
Lasso di tempo: DSMC Schedule
|
The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
|
DSMC Schedule
|
To evaluate DCE-MRI as a surrogate of response to PTK787/ZK222584 therapy in pancreatic cancer patients.
Lasso di tempo: DSMC Schedule
|
The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
|
DSMC Schedule
|
To perform analysis of tissue, blood and plasma markers that may be helpful in assessing the likelihood of benefit from PTK787/ZK222584 therapy.
Lasso di tempo: DSMC Schedule
|
The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
|
DSMC Schedule
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Tomislav Dragovich, MD, PhD, University of Arizona/Arizona Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PCRT04-001
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su PTK787/ZK222584
-
David Rizzieri, MDNovartis PharmaceuticalsTerminatoLinfoma, a grandi cellule, diffusoStati Uniti
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletatoMesotelioma malignoStati Uniti
-
Novartis PharmaceuticalsCompletatoMalattia di Von Hippel-Lindau | Emangioblastoma retinico | Emangioblastoma del SNCStati Uniti
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletatoSindromi mielodisplastiche | Leucemia | Neoplasie mielodisplastiche/mieloproliferativeStati Uniti
-
NovartisBayerCompletatoNeoplasie colorettali | Neoplasie Rettali | Neoplasie del colonBelgio, Germania, Italia, Stati Uniti, Taiwan, Svizzera, Spagna, Canada, Slovacchia, Regno Unito, Nuova Zelanda, Australia, Portogallo, Brasile, Ungheria, Cechia, Francia, Olanda, Svezia
-
University of HelsinkiBayerCompletato
-
BayerCompletatoCarcinoma polmonare non a piccole celluleFrancia, Germania
-
George Albert FisherNovartisCompletato
-
Novartis PharmaceuticalsBayerCompletatoNeoplasie colorettali | Neoplasie Rettali | Neoplasie del colonStati Uniti, Germania, Belgio, Canada, Spagna, Regno Unito, Taiwan, Francia, Svizzera, Svezia, Portogallo, Nuova Zelanda, Italia, Slovacchia, Australia, Austria, Brasile, Hong Kong